| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5878283 | The American Journal of Medicine | 2014 | 47 Pages |
Abstract
In contemporary practice of treatment of myocardial infarction, β-blockers have no mortality benefit but reduce recurrent myocardial infarction and angina (short-term) at the expense of increase in heart failure, cardiogenic shock, and drug discontinuation. The guideline authors should reconsider the strength of recommendations for β-blockers post myocardial infarction.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Sripal MD, MHA, Harikrishna MD, Martha MD, Kamia MD, Bora MD, Stuart D. MD, James J. PharmD, P.J. MD, PhD, Karen P. MD, Jorn MD, PhD, Franz H. MD,